TABLE 3.

Effect of compounds injected into the brain of Tg7 mice^a

Treatment (50 μl in PBS)	Days of dose (postinoculation)	Survival timesb (days)	Mean survival time ± SD	Control mean survival time ± SD
0.5 mM FeTAP	14, 16, 18, 21c	45, 51, 51, 54, 54, 60, 60, 60	54.4 ± 5.4d	46.1 ± 1.2
0.5 mM FeTAP	14, 21, 28, 35, 42	46, 47, 47, 47, 47, 48, 56, 57	49.4 ± 4.4	48.3 ± 3.0
0.5 mM NiTAP	13, 20, 27, 34, 41	44, 44, 49, 49, 49, 61, 61	50.1 ± 7.2	48.7 ± 6.8
0.25 mM PdTAP	13, 20, 27, 34, 41	43, 49, 51, 56	49.8 ± 5.4	48.7 ± 6.8
0.1 mM ZnTAP	13, 20, 27, 34, 41	49, 49, 50, 50, 51, 51, 53, 63	52.0 ± 4.6	48.7 ± 6.8
0.1 mM TAP	13, 20, 27, 34, 41	43, 44, 49, 49, 49, 51, 54, 54, 54	49.7 ± 4.1	48.7 ± 6.8
0.5 mM ZnTSP	13, 20, 27, 34, 41	47, 49, 49, 50, 51, 53, 53, 54, 57, 65	52.8 ± 5.2	48.7 ± 6.8
0.5 mM InTSP	13, 20, 27, 34, 41	44, 49, 51, 53, 54, 54, 56, 57, 65	53.7 ± 5.8	48.7 ± 6.8
0.5 mM FeTSP	13, 20, 27, 34, 41	57, 68, 70, 70, 72, 73, 83, 83, 85	73.4 ± 9.0e	48.7 ± 6.8
0.5 mM FeTSP	14, 21, 28, 35, 42, 49	54, 68, 68, 74, 76, 76, 80	70.9 ± 8.6e	50.6 ± 3.0
0.16 mM FeTSP	14, 21, 28, 35, 42, 49	54, 56, 56, 61, 64, 66, 66, 67	61.3 ± 5.3d	50.6 ± 3.0
0.05 mM FeTSP	14, 21, 28, 35, 42, 49	52, 54, 57, 60, 62, 62, 64, 67	59.8 ± 5.1d	50.6 ± 3.0
∼0.05 mM PPSf	14, 21, 28, 35, 42	67, 68, 70, 72, 73, 73, 77, 78	72.3 ± 3.9e	48.3 ± 3.0

^aCompounds were dosed after i.c. inoculation with 50 μl of 1% 263K-infected brain homogenate. A control group of eight Tg7 mice dosed i.c. with 50 μl of phosphate-buffered saline (PBS) at the same interval as that of treated mice was included with each experiment.

^bMice dying from nonscrapie causes were removed from the data set.

^cDosing was halted due to observed toxicity.

^dP < 0.001 versus corresponding control group by unpaired t test.

^eP < 0.0001 versus corresponding control group by unpaired t test.

^fThis concentration was based on the average molecular weight of ∼5,000.